Overview |
|
Repromedix is the leading national diagnostic laboratory for fertility testing. The company takes a multifaceted approach to clinical fertility that encompasses many medical disciplines including endocrinology, immunology and genetics testing. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. |
Signature Tests |
- Plan Ahead™ test – the most advanced test of a woman’s ovarian reserve
- Sperm DNA Decondensation™ (SDD) Test – male factor infertility
- Sperm DNA Fragmentation Assay™ (SDFA) – male factor infertility
- Anti-ß2Glycoprotein I Test – early/recurrent pregnancy loss
- Antithrombin Activity –Thrombophilia
|
Comprehensive Panels |
- Recurrent Pregnancy Loss
- Unexplained Infertility or Implantation Failure
- Male Factor Infertility
- Ovarian Reserve
- Thrombophilia
|
Value-Added Services |
- Direct insurance billing
- Prepaid specimen transportation
- Stringent quality control
- Physician guidance upon request
- Indicated treatments for all positive tests
|
Corporate Leadership |
| Michael Burns, PhD | | Chief Executive Officer |
| Karen Vernamonti | Chief Operating Officer & Chief Financial Officer |
| Benjamin Rivnay, Ph.D. | Vice President of R&D & Laboratory Director |
| Benjamin Leader, MD, PhD | Chief Medical Officer |
| Paul Kowalski | Vice President of Sales |
|
Funding |
Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors |
Headquarters |
Woburn, MA |
Media Contacts |
Lisa Scimemi
781-404-1752
lscimemi@repromedix.com
Julie Dennehy
508-533-8311
Julie@dennehypr.com
|
